In 1994, Oncaspar® has been approved by the USFDA for the treatment only of acute lymphoblastic leukemia (ALL) patients who were allergic to the cancer drug L-asparaginase.

Now, the USFDA has granted extended approval of Oncaspar® to include treatment of children and adults with newly diagnosed acute lymphoblastic leukemia (ALL) as part of a multiple drug chemotherapy regimen.

Oncaspar® is one of the first FDA-approved products that include prescription information in a new format intended to provide clear and concise information to health professionals.

"Today's announcement further demonstrates FDA's commitment to improving the quality of life for cancer patients. This treatment is a valuable alternative to current therapy," said Dr. Steven Galson, Director of FDA's Center for Drug Evaluation and Research.

Read more at USFDA News.